Drugs for Exudative Vitreoretinopathy 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 159)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Zinc cation |
Approved, Experimental, Investigational |
Phase 4 |
|
7440-66-6, 23713-49-7 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
Mannosidase b, alpha
Neutral alpha mannosidase
|
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc ion(2+)
Zinc(2+)
Zinc(II)
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
zinc|zinc ion
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
2 |
|
Zinc sulfate |
Approved, Investigational |
Phase 4 |
|
7733-02-0 |
|
Synonyms:
Zinc sulfate (anhydrous)
Zinc sulfate anhydrous
Zinc sulfate, anhydrous
|
Zinc sulphate
Zinc sulphate anhydrous
Zinc sulphate, anhydrous
|
|
3 |
|
Ketamine |
Approved, Vet_approved |
Phase 4 |
|
6740-88-1, 1867-66-9 |
3821 |
Synonyms:
(-)-Ketamine
(+-)-Ketamine
(±)-ketamine
(S)-(-)-Ketamine
(S)-Ketamine
2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(O-Chlorophenyl)-2-(methylamino)-cyclohexanone
Calipsol
Calypsol
CI 581 base
CLSTA 20
DL-Ketamine
Esketamine
Kalipsol
Ketaject
Ketalar
|
Ketalar base
Ketalar|ketamine HCl
Ketamina
KETAMINE
Kétamine
Ketamine base
Ketamine HCL
Ketamine hydrochloride
Ketaminum
Ketanest
Ketaset
Ketolar
L-Ketamine
NMDA
NSC-70151
Special K
Tekam
|
|
4 |
|
Nitrous oxide |
Approved, Vet_approved |
Phase 4 |
|
10024-97-2 |
948 |
Synonyms:
Diazyne 1-oxide
Dinitrogen monoxide
Dinitrogen oxide
Distickstoffmonoxid
e942
Factitious air
FEMA 2779
Gas, laughing
Gaz hilarant
Hyponitrous acid anhydride
Lachgas
Laughing gas
N2O
Nitral
Nitrious oxide
Nitrogen hypoxide
Nitrogen monoxide
Nitrogen oxide (N2O)
|
Nitrogen protoxide
Nitrogenium oxydulatum
Nitrous oxide
Nitrous oxide (JP15/usp)
Nitrous oxide, compressed
Nitrous oxide, jan, usan
Nitrous oxide, refrigerated liquid
Nitrous-oxide
NNO
Oxide, nitrous
oxido Nitroso
óxido nitroso
Oxidodinitrogen(N--N)
Oxyde nitreux
Protoxyde d'azote
R-744a
Stickdioxyd
Stickstoff(I)-oxid
|
|
5 |
|
Sevoflurane |
Approved, Vet_approved |
Phase 4 |
|
28523-86-6 |
5206 |
Synonyms:
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
Fluoromethyl hexafluoroisopropyl ether
Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
HFE-347MMZ1
MR6S4
MR-6S4
Sevofluran
SEVOFLURANE
|
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevorane
SOJOURN
Ultane
|
|
6 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 4 |
|
2078-54-8 |
4943 |
Synonyms:
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Diisopropylphenol
2,6-diisopropylphenol|Diprivan®|ICI 35868
Abbott brand OF propofol
Alpha Brand OF propofol
Aquafol
Astra brand OF propofol
AstraZeneca brand OF propofol
Braun brand OF propofol
Curamed brand OF propofol
Diisopropylphenol
Diprivan
Disoprivan
Disoprofol
Fresenius brand OF propofol
Fresenius kabi brand OF propofol
Fresofol
ICI 35868
ICI 35-868
|
ICI35,868
ICI-35868
Ivofol
Juste brand OF propofol
NSC-5105
Parnell brand OF propofol
Pisa brand OF propofol
Propofol
Propofol abbott
Propofol fresenius
Propofol MCT
Propofol rovi
Propofol-lipuro
Propofolum
Rapinovet
Recofol
Rovi brand OF propofol
Schering brand OF propofol
Zeneca brand OF propofol
|
|
7 |
|
Cyclopentolate |
Approved |
Phase 4 |
|
512-15-2 |
2905 |
Synonyms:
(+-)-Cyclopentolate
(+-)-Cyclopentolic acid
(±)-CYCLOPENTOLATE
1-Hydroxy-alpha-phenylcyclopentaneacetate 2-(dimethylamino)ethyl ester
1-Hydroxy-alpha-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester
1-Hydroxy-a-phenylcyclopentaneacetate 2-(dimethylamino)ethyl ester
1-Hydroxy-a-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester
1-Hydroxy-α-phenylcyclopentaneacetate 2-(dimethylamino)ethyl ester
1-Hydroxy-α-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester
2-(Dimethylamino)ethyl 1-hydroxy-alpha-phenylcyclopentaneacetate
2-(Dimethylamino)ethyl 1-hydroxy-alpha-phenylcyclopentaneacetic acid
2-(Dimethylamino)ethyl 1-hydroxy-a-phenylcyclopentaneacetate
2-(Dimethylamino)ethyl 1-hydroxy-a-phenylcyclopentaneacetic acid
2-(Dimethylamino)ethyl 1-hydroxy-α-phenylcyclopentaneacetate
2-(Dimethylamino)ethyl 1-hydroxy-α-phenylcyclopentaneacetic acid
2-(Dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate
2-(Dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetic acid
2-Phenyl-2-(1-hydroxycyclopentyl)ethanoate b-(dimethylamino)ethyl ester
2-Phenyl-2-(1-hydroxycyclopentyl)ethanoate beta-(dimethylamino)ethyl ester
2-Phenyl-2-(1-hydroxycyclopentyl)ethanoate β-(dimethylamino)ethyl ester
2-Phenyl-2-(1-hydroxycyclopentyl)ethanoic acid b-(dimethylamino)ethyl ester
2-Phenyl-2-(1-hydroxycyclopentyl)ethanoic acid beta-(dimethylamino)ethyl ester
2-Phenyl-2-(1-hydroxycyclopentyl)ethanoic acid β-(dimethylamino)ethyl ester
a-(1-Hydroxycyclopentyl)benzeneacetate 2-(dimethylamino)ethyl ester
a-(1-Hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester
alpha-(1-Hydroxycyclopentyl)benzeneacetate 2-(dimethylamino)ethyl ester
|
alpha-(1-Hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester
b-(Dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate
b-(Dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetic acid
b-Dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate
b-Dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetic acid
Bell pentolate
Bell pentolic acid
beta-(Dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate
beta-(Dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetic acid
beta-Dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate
beta-Dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetic acid
Ciclopentolato
Cyclogyl
Cyclopentoiate
CYCLOPENTOLATE
Cyclopentolatum
Cyclopentolic acid
Cyclopentylate
Diopentolate
MYDRILATE
Α-(1-hydroxycyclopentyl)benzeneacetate 2-(dimethylamino)ethyl ester
Α-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester
Î’-(dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate
Î’-(dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetic acid
Î’-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate
Î’-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetic acid
|
|
8 |
|
Dipivefrin |
Approved |
Phase 4 |
|
52365-63-6 |
3105 |
Synonyms:
(+-)-4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalate
(+-)-4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalic acid
(±)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate
1-(3',4'-Dipivaloyloxyphenyl)-2-methylamino-1-ethanol
4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalate
4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalic acid
Adrenaline dipivalate
Alcon brand OF dipivefrin hydrochloride
Allergan brand OF dipivefrin hydrochloride
Apo-dipivefrin
Apotex brand OF dipivefrin hydrochloride
D Epifrin
Diopine
Dipivaloylepinephrine
Dipivalyl epinephrine
Dipivefrin
Dipivefrin acetate, (+-)-isomer
Dipivefrin citrate (1:1), (+-)-isomer
Dipivefrin hydrochloride
Dipivefrin hydrochloride, (+-)-isomer
Dipivefrin monophosphate, (+-)-isomer
Dipivefrin monosulfate, (+-)-isomer
|
Dipivefrin nitrate, (+-)-isomer
Dipivefrin perchlorate
Dipivefrin propanoate, (+-)-isomer
Dipivefrin tartrate (1:1), (+-)-(R-(r*,r*))-isomer
Dipivefrin tartrate (1:1), (R)-(R-(r*,r*))-isomer
Dipivefrin, (R)-isomer
Dipivefrina
Dipivefrine
Dipivéfrine
Dipivefrinum
Dipoquin
DPE
Glaucothil
Glaudrops
Ioquin brand OF dipivefrin hydrochloride
Pharm-allergan brand OF dipivefrin hydrochloride
Pharmascience brand OF dipivefrin hydrochloride
PMS-Dipivefrin
PRO-EPINEPHRINE
Propine
Ratio-dipivefrin
Ratiopharm brand OF dipivefrin hydrochloride
|
|
9 |
|
Racephedrine |
Approved, Experimental |
Phase 4 |
|
299-42-3, 90-82-4, 90-81-3 |
5032 9294 7028 |
Synonyms:
(-)-Ephedrine
(+) Threo-2-(methylamino)-1-phenyl-1-propanol
(+)-(1S,2S)-Pseudoephedrine
(+-)-Ephedrine
(+)-Pseudoephedrine
(+)-Psi-ephedrine
(+)-Threo-ephedrine
(1R,2S)-1-Phenyl-1-hydroxy-2-methylaminopropane
(1S,2S)-(+)-Pseudoephedrine
(1S,2S)-Pseudoephedrine
1-Ephedrine
2-(Methylamino)-1-phenyl-1-propanol
Acunaso
Besan
D-Isoephedrine
D-Pseudoephedrine
D-Pseudoephedrine base
D-Psi-2-methylamino-1-phenyl-1-propanol
D-Psi-ephedrine
Efedrina
Emerphed® (ephedrine sulfate injection)
Ephedrine
Ephedrine DL-form
Ephedrine erythro isomer
Ephedrine hydrochloride
Ephedrine renaudin
Ephedrine sulfate
Ephedrine threo isomer
Erythro isomer OF ephedrine
Hydrochloride, ephedrine
Isoephedrine
L(-)-Ephedrine
L(−)-EPHEDRINE
|
L-(+)-Pseudoephedrine
L(+)-Psi-ephedrine
L-Ephedrine
L-Erythro-2-(methylamino)-1-phenylpropan-1-ol
Neodurasina
Novafed
NSC-170951
NSC-8971
Pseudoefedrina
Pseudoephedrine
pseudoéphédrine
Pseudoephedrine D-form
Pseudoephedrine ephedrine
Pseudoephedrine HCL
Pseudoephedrine hydrochloride
Pseudoephedrinum
PSEUDOPHEDRINE SULPHATE
Psi-ephedrin
Psi-ephedrine
Racephedrine
Renaudin brand OF ephedrine hydrochloride
Renaudin, ephedrine
Sal phedrine
Sal-phedrine
SalPhedrine
SINUTAB
Sudafed
Sulfate, ephedrine
Threo isomer OF ephedrine
trans-Ephedrine
Wendt brand OF ephedrine sulfate
ψ-ephedrine
|
|
10 |
|
Phenylephrine |
Approved |
Phase 4 |
|
59-42-7 |
6041 |
Synonyms:
(-)-m-Hydroxy-a-(methylaminomethyl)benzyl alcohol
(-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol
(−)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
(-)-m-Hydroxy-α-(methylaminomethyl)benzyl alcohol
(R)-3-[-1-HYDROXY-2-(METHYLAMINO)ETHYL]PHENOL
(R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol
AB-101 (PHENYLEPHRINE)
Adrianol
Ak-dilate
Ak-nefrin
Alcon efrin
Alconefrin nasal drops 12
Alconefrin nasal drops 25
Alconefrin nasal drops 50
Alconefrin nasal spray 25
BENZENEMETHANOL, 3-HYDROXY-.ALPHA.-[(METHYLAMINO)METHYL]-, (R)-
BENZENEMETHANOL, 3-HYDROXY-ALPHA-((METHYLAMINO)METHYL)-, (R)-
BENZYL ALCOHOL, M-HYDROXY-ALPHA-((METHYLAMINO)METHYL)-, (-)-
Biomydrin
CYCLOMYDRIL
Dilatair
Dimetane
Dionephrine
Doktors
DUO-MEDIHALER
Duration
Fenilefrina
Fenilefrina [INN-Spanish]
I-phrine
Isophrim
Isophrin
Isopto frin
J8.601K
L-(3-Hydroxyphenyl)-N-methylethanolamine
L-Phenylephedrine
L-Phenylephrine
Mesaton
Mesatone
Mesatonum
Metaoxedrin
Metaoxedrine
Metaoxedrinum
Metasympatol
Metasynephrine
|
Metsatonum
Mezaton
Minims phenylephrine
m-Methylaminoethanolphenol
m-Oxedrine
m-oxedrine|metasynephrine
m-Sympathol
m-Sympatol
m-Synephrine
Mydfrin
Neo synephrine
Neofrin
Neophryn
Neosynephrine
Neo-synephrine
Neo-synephrine nasal drops
Neo-synephrine nasal jelly
Neo-synephrine nasal spray
Neo-synephrine pediatric nasal drops
Nostril
Nostril spray pump
Nostril spray pump mild
Ocugestrin
Ocu-phrin sterile eye drops
Ocu-phrin sterile ophthalmic solution
PEF100
Phenoptic
PHENYLEPHRINE
Phenylephrine hydrochloride
Phenylephrine minims
Phenylephrine tannate
Phenylephrinum
Phenylephrinum [INN-Latin]
Prefrin
Prefrin liquifilm
Pyracort D
R(-)-Mezaton
R(-)-Phenylephrine
Relief eye drops for red eyes
Rhinall
Spersaphrine
Tannate, phenylephrine
Vicks sinex
Visadron
|
|
11 |
|
Tropicamide |
Approved, Investigational |
Phase 4 |
|
1508-75-4 |
5593 |
Synonyms:
Akorn brand OF tropicamide
Alcon brand OF tropicamide
Bournonville brand OF tropicamide
Cahill may roberts brand OF tropicamide
Chauvin brand OF tropicamide
Colircusi tropicamida
Medical ophthalmics brand OF tropicamide
Minims tropicamide
MYD947
Mydral
Mydriacyl
Mydriacyl®
Mydriafair
Mydriaticum
Mydrum
N-Ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)benzeneacetamide
N-Ethyl-N-(4-pyridylmethyl)tropamide
NODS
Novartis brand OF tropicamide
Ocu tropic
Ocumed brand OF tropicamide
Ocusoft brand OF tropicamide
Ocu-tropic
OcuTropic
Pharmafair brand OF tropicamide
|
Rivex brand OF tropicamide
RO-1-7683
Stulln brand 1 OF tropicamide
Stulln brand 2 OF tropicamide
Triaminic DM
Tropicacyl
TROPICAMID
TROPICAMIDA
TROPICAMIDE
Tropicamide alcon brand
Tropicamide chauvin brand
Tropicamide faure
Tropicamide minims
Tropicamide monofree
Tropicamide monohydrochloride, (R)-isomer
Tropicamide monohydrochloride, (S)-isomer
Tropicamide novartis brand
Tropicamide ocumed brand
Tropicamide pharmafair brand
Tropicamide rivex brand
Tropicamide, (+-)-isomer
Tropicamide, (R)-isomer
Tropicamide, (S)-isomer
TROPICAMIDUM
|
|
12 |
|
Oxymetazoline |
Approved, Investigational |
Phase 4 |
|
1491-59-4 |
4636 |
Synonyms:
2-(4-Tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
6-Tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
Afrin
Afrin®|oxymethazoline|SCH-9384|Upneeq® (opthalmic solution)|Vicks Sinex®
Hydrochloride, oxymetazoline
OCUCLEAR
Operil
Oximetazolinum
|
Oxymetazolina
OXYMETAZOLINE
Oxymétazoline
Oxymetazoline hydrochloride
Oxymetazoline hydrochloride crystalline
Oxymetazolinum
Oxymethazoline
Oxymetozoline
SCH-9384
VICKS SINEX
|
|
13 |
|
Clonidine |
Approved |
Phase 4 |
|
4205-91-8, 4205-90-7 |
2803 20179 |
Synonyms:
2-((2,6-Dichlorophenyl)imino)imidazolidine
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
2-[(2,6-Dichlorophenyl)imino]imidazoline
Adesipress
Boehringer ingelheim brand OF clonidine hydrochloride
Catapres
CATAPRES P.L.
CATAPRES TTS 1
CATAPRES TTS 2
CATAPRES TTS 3
Catapres®|Kapvay®
Catapresan
Catapressan
Catapres-TTS
CATAPRES-TTS-1
CATAPRES-TTS-2
CATAPRES-TTS-3
Catarpres
Catarpresan
Catarpres-TTS
Chlofazoline
Chlophazolin
Chlornidinum
Clofelin
Clofenil
Clonidin
Clonidina
Clonidine
Clonidine dihydrochloride
CLONIDINE HCL
Clonidine hydrochloride
|
Clonidine monohydrobromide
Clonidine monohydrochloride
Clonidinhydrochlorid
Clonidinum
Clonidinum [INN-Latin]
Clonistada
Clopheline
CLORPRES
COMBIPRES
DICHLORANILINO IMIDAZOLIN
Dihydrochloride, clonidine
Dixarit
DURACLON
Duraclont
Gemiton
Hemiton
Hydrochloride, clonidine
Ipotensium
Isoglaucon
JENLOGA
KAPVAY
KAPVAY®
Klofelin
Klofenil
Monohydrobromide, clonidine
Monohydrochloride, clonidine
ST 155BS
ST-155
ST-155BS
ST-155-BS
Tenso-Timelets
|
|
14 |
|
Ketorolac |
Approved |
Phase 4 |
|
74103-06-3, 66635-83-4 |
3826 |
Synonyms:
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
(+-)-Ketorolac
ACULAR
Acular LS
Acular Preservative Free
Acular®|Toradol®
Ketoralac
Ketorolac
|
Kétorolac
Ketorolac tromethamine
Ketorolaco
Ketorolaco [Spanish]
Ketorolacum
Ketorolacum [Latin]
rac-Ketorolac
Toradol
|
|
15 |
|
Vitamin A |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
22737-96-8, 68-26-8 |
5280382 445354 |
Synonyms:
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-EN-1-YL)NONA-2,4,6,8-TETRAEN-1-OL
(ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAEN-1-OL
11-CIS-RETINOL
11-cis-Vitamin a alcohol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-e)-isomer
all trans Retinol
all-trans-Retinol
ALL-TRANS-RETINYL ALCOHOL
ALL-TRANS-VITAMIN A ALCOHOL
ALPHALIN
Aquasol a
AROVIT
BETA-RETINOL
B-RETINOL
CHOCOLA A
cis-11-Retinol
|
NEPALM
NSC-122759
OLEOVITAMIN A
Retinol
RETINOL (VIT A)
RETINOL ACETATE
RETINOL PALMITATE
Retinolum
RO-A-VIT
TRANS-RETINOL
Vitamin a
VITAMIN A 1
VITAMIN A OIL
VITAMIN A SOLUBILIZED
Vitamin a1
|
|
16 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
17 |
|
Neuromuscular Blocking Agents |
|
Phase 4 |
|
|
|
18 |
|
Excitatory Amino Acid Antagonists |
|
Phase 4 |
|
|
|
19 |
|
Platelet Aggregation Inhibitors |
|
Phase 4 |
|
|
|
20 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
21 |
|
Anesthetics, Inhalation |
|
Phase 4 |
|
|
|
22 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
23 |
|
Anesthetics, Dissociative |
|
Phase 4 |
|
|
|
24 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
25 |
|
Vitamins |
|
Phase 4 |
|
|
|
26 |
|
Trace Elements |
|
Phase 4 |
|
|
|
27 |
|
Micronutrients |
|
Phase 4 |
|
|
|
28 |
|
Retinol palmitate |
|
Phase 4 |
|
|
|
29 |
|
Antioxidants |
|
Phase 4 |
|
|
|
30 |
|
Parasympatholytics |
|
Phase 4 |
|
|
|
31 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
32 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
33 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
34 |
|
Cardiotonic Agents |
|
Phase 4 |
|
|
|
35 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
36 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
37 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
38 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
39 |
|
Muscarinic Antagonists |
|
Phase 4 |
|
|
|
40 |
|
Cholinergic Antagonists |
|
Phase 4 |
|
|
|
41 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
42 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
43 |
|
Protective Agents |
|
Phase 4 |
|
|
|
44 |
|
Nasal Decongestants |
|
Phase 4 |
|
|
|
45 |
|
Sympatholytics |
|
Phase 4 |
|
|
|
46 |
|
Analgesics |
|
Phase 4 |
|
|
|
47 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
48 |
|
Ketorolac Tromethamine |
|
Phase 4 |
|
|
|
Synonyms:
ACULAR
ACULAR LS
ACULAR PRESERVATIVE FREE
ACUVAIL
|
KETOROLAC TROMETHAMINE
SPRIX
TORADOL
|
|
49 |
|
Cyclooxygenase Inhibitors |
|
Phase 4 |
|
|
|
50 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 139)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Oral Zinc Supplementation Improving Growth and Reducing Morbidity on Very Low Birth Weight Infant |
Unknown status |
NCT04050488 |
Phase 4 |
Zinc Sulfate;Placebos |
2 |
DECREASING THE NEED FOR MECHANICAL VENTILATION AFTER RETINOPATHY OF PREMATURITY SURGERY: Sedation vs General Anesthesia |
Completed |
NCT01955135 |
Phase 4 |
Ketamine;Sevoflurane;propofol |
3 |
Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage V. |
Completed |
NCT00500396 |
Phase 4 |
|
4 |
Does Additional Vitamin A Supplementation Improve Retinal Function and Conjunctival Health in Very Low Birthweight Infants? |
Completed |
NCT00417404 |
Phase 4 |
Aquasol A;aquasol A |
5 |
Efficacy and Safety of Mydriatic Microdrops Compared With Standard Drops for Retinopathy of Prematurity (ROP) Screening: a Pilot Randomized Clinical Trial |
Completed |
NCT04623684 |
Phase 4 |
Microdrop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 6-7 μL)];Standard drop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 28-34 μL)] |
6 |
Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage IV and V |
Completed |
NCT00563121 |
Phase 4 |
|
7 |
Sucrose and Non Nutritive Suck as Analgesia for Babies Undergoing Retinopathy of Prematurity Screening; a Randomised Placebo Controlled Trial |
Completed |
NCT00921544 |
Phase 4 |
|
8 |
Comparison of the Vascular Endothelial Growth Factor Serum Concentrations After Intravitreal Use of Bevacizumab or Ranibizumab as a Treatment for Type 1 Retinopathy of Prematurity |
Completed |
NCT03148132 |
Phase 4 |
Bevacizumab Injection;Ranibizumab Ophthalmic |
9 |
Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study |
Completed |
NCT04838665 |
Phase 4 |
0.5% cyclopentolate and 2.5% phenylephrine;0.5% tropicamide + 0.5% phenylephrine;0.5% tropicamide + 0.5% phenylephrine with a cotton wick |
10 |
Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening: a Non-inferiority Crossover Randomized Controlled Trial (MyMiROPS Trial) |
Recruiting |
NCT05043077 |
Phase 4 |
Microdrop administration of phenylephrine 1.67% and tropicamide 0.33%;Standard drop administration of phenylephrine 1.67% and tropicamide 0.33% |
11 |
Clonidine as Pain Relief During ROP Eye Examinations |
Recruiting |
NCT04902859 |
Phase 4 |
Clonidine Oral Liquid Product;Sterile water |
12 |
Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity |
Terminated |
NCT00634972 |
Phase 4 |
ACULAR;REFRESH TEARS;placebo |
13 |
Fasudil Eye Drop in Retinopathy Of Prematurity, Retinal Vascularization Induction and Disease Progression Inhibition, a Randomized Clinical Trial |
Unknown status |
NCT04191954 |
Phase 2, Phase 3 |
Fasudil eye drops (concentration 0.5 percent);receive artificial tears drop |
14 |
The Early Treatment for Retinopathy of Prematurity Study (ETROP) |
Unknown status |
NCT00027222 |
Phase 2, Phase 3 |
|
15 |
Effect of Cysteine Supplementation on Glutathione Production in Critically Ill Neonates |
Unknown status |
NCT00254176 |
Phase 2, Phase 3 |
|
16 |
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome |
Unknown status |
NCT00346814 |
Phase 2, Phase 3 |
intravitreal injection |
17 |
A Randomised Intervention Single Center Study to Determine the Role of Fatty Acids in Serum in Preventing Retinopathy of Prematurity |
Completed |
NCT02760472 |
Phase 3 |
SMOFlipid;Clinoleic |
18 |
Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity |
Completed |
NCT04101721 |
Phase 3 |
aflibercept |
19 |
RAINBOW Study: a Randomized, Controlled Study Evaluating the Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity |
Completed |
NCT02375971 |
Phase 3 |
Ranibizumab |
20 |
Open-label, Randomized, Two-Arm, Controlled Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal (IVT) Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity (ROP) |
Completed |
NCT04004208 |
Phase 3 |
Eylea (Aflibercept, BAY86-5321) |
21 |
A Randomized Controlled Trial on the Effectiveness of Inhaled Nitrous Oxide for Pain Relief During ROP Screening Exam in the Pre-term Infant |
Completed |
NCT00623220 |
Phase 3 |
|
22 |
Safety and Efficacy of Treatment With Propranolol in Newborns With Retinopathy of Prematurity: a Pilot Study |
Completed |
NCT01079715 |
Phase 2, Phase 3 |
Propranolol |
23 |
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants |
Completed |
NCT00233324 |
Phase 3 |
Surfactant;Supplemental oxygen with target saturation of 85 to 89%;Supplemental oxygen with target saturation of 91 to 95% |
24 |
The Effects of Light Reduction on Retinopathy of Prematurity (Light-ROP) |
Completed |
NCT00000156 |
Phase 3 |
|
25 |
Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity |
Completed |
NCT01203436 |
Phase 2, Phase 3 |
|
26 |
A Randomized Trial of Low-Dose Bevacizumab Versus Laser for Type 1 Retinopathy of Prematurity |
Recruiting |
NCT04634604 |
Phase 3 |
Bevacizumab |
27 |
Comparison Between Intravitreal Injection of Ranibizumab and Bevacizumab for Treatment of Type 1 Retinopathy of Prematurity |
Recruiting |
NCT05033106 |
Phase 3 |
Bevacizumab, Ranibizumab |
28 |
RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity |
Active, not recruiting |
NCT02640664 |
Phase 3 |
Ranibizumab |
29 |
An Extension Study to Evaluate the Long-term Outcomes of Subjects Who Received Treatment for Retinopathy of Prematurity in Study 20090 |
Active, not recruiting |
NCT04015180 |
Phase 3 |
Eylea (Aflibercept, BAY86-5321) |
30 |
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants |
Terminated |
NCT01954082 |
Phase 3 |
myo-Inositol 5% Injection;Placebo |
31 |
Safety and Efficacy of Propranolol Treatment in Newborns With Retinopathy of Prematurity:a Prospective Cohort Study |
Unknown status |
NCT03038295 |
Phase 2 |
Propranolol;placebo |
32 |
Early Treatment With Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants: Comparison of High and Low Dose |
Unknown status |
NCT00910234 |
Phase 1, Phase 2 |
recombinant human erythropoietin (rhEpo);Normal saline |
33 |
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial |
Unknown status |
NCT00622726 |
Phase 2 |
Bevacizumab |
34 |
Multicenter Randomized Double Masked Parallel Design Exploratory Study to Assess Safety and Efficacy of Two Different Doses of Intravitreal Anti-VEGF Treatment With Ranibizumab (0.12 mg vs. 0.20 mg) in Infants With Retinopathy of Prematurity (ROP) |
Completed |
NCT02134457 |
Phase 2 |
|
35 |
Safety and Efficacy of Propranolol Eye Drops in Newborns With Retinopathy of Premature (DROP-PROP) |
Completed |
NCT02014454 |
Phase 2 |
Propranolol eye drops |
36 |
Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP STUDY) |
Completed |
NCT02344225 |
Phase 2 |
Caffeine citrate;Ibuprofen;Ketorolac |
37 |
Phase II Randomized, Double-Masked, Placebo-Controlled, Safety, Pharmacokinetic, and Dose-Ranging Study of Multiple Doses of Inositol in Premature Infants |
Completed |
NCT01030575 |
Phase 2 |
Inositol lower volume;Inositol mid-level volume;Inositol high volume;Placebo low volume |
38 |
Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants |
Completed |
NCT00349726 |
Phase 2 |
Inositol lower volume;Inositol higher volume;Placebo lower volume;Placebo higher volume |
39 |
Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated With rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care |
Completed |
NCT02386839 |
Phase 2 |
rhIGF-1/rhIGFBP-3 |
40 |
Safety and Efficacy of Propranolol 0.2% Eye Drops in Treating Newborn With Retinopathy of Premature: A Pilot Study (DROP-ROP-0.2%) |
Completed |
NCT02504944 |
Phase 2 |
Propranolol 0.2% eye drops |
41 |
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study |
Completed |
NCT01096784 |
Phase 2 |
rhIGF-I/rhIGFBP-3 |
42 |
Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity: Proposal for a Prospective Randomized Controlled Masked Clinical Trial With Lipidomic and Transcriptomic Analyses |
Completed |
NCT02486042 |
Phase 2 |
Omegaven |
43 |
Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity (ROP): A Pilot, Randomized and Prospective Study. |
Completed |
NCT01238471 |
Phase 1, Phase 2 |
propranolol;sucrose 5% |
44 |
PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity |
Recruiting |
NCT04621136 |
Phase 1, Phase 2 |
Ripasudil ophthalmic solution 0.4% |
45 |
Bevacizumab Treatment For Posterior Zone I Retinopathy of Prematurity |
Recruiting |
NCT04634578 |
Phase 2 |
Bevacizumab |
46 |
Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity |
Recruiting |
NCT03083431 |
Phase 2 |
Propranolol;Placebo |
47 |
Umbilical or Adult Donor Red Blood Cells to Transfuse Extremely Low Gestational Age Neonates. A Randomized Trial to Assess the Effect on Retinopathy of Prematurity Severity. |
Recruiting |
NCT05100212 |
Phase 2 |
|
48 |
A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compared to Standard Neonatal Care in Extremely Premature Infants |
Active, not recruiting |
NCT03253263 |
Phase 2 |
SHP607 |
49 |
Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP) |
Withdrawn |
NCT01232777 |
Phase 2 |
Bevacizumab |
50 |
Safety and Effectiveness Phase 1 Study of Autologous Umbilical Cord Blood Transfusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates |
Unknown status |
NCT02050971 |
Phase 1 |
|
|